Shortly after thalidomide was released to market in the 1950s, a reported 10,000 infants were born with an extreme form of a rare congenital syndrome — phocomelia — which caused death in 50 percent of cases. Now, half a century later, new research has identified a regulator responsible for the malformation of limbs in phocomelia, pinpointing a specific target for possible future intervention.